Carnegie Investment Counsel’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.13M | Sell |
129,803
-31,214
| -19% | -$817K | 0.06% | 202 |
|
|
2026
Q1 | $4.52M | Buy |
161,017
+6,467
| +4% | +$172K | 0.09% | 183 |
|
|
2025
Q4 | $3.85M | Buy |
154,550
+110,759
| +253% | +$2.79M | 0.07% | 202 |
|
|
2025
Q3 | $1.12M | Sell |
43,791
-4,140
| -9% | -$102K | 0.02% | 301 |
|
|
2025
Q2 | $1.16M | Sell |
47,931
-7,395
| -13% | -$172K | 0.02% | 291 |
|
|
2025
Q1 | $1.28M | Buy |
55,326
+7,557
| +16% | +$198K | 0.03% | 264 |
|
|
2024
Q4 | $1.27M | Sell |
47,769
-55,877
| -54% | -$1.52M | 0.04% | 242 |
|
|
2024
Q3 | $3M | Sell |
103,646
-6,379
| -6% | -$186K | 0.09% | 176 |
|
|
2024
Q2 | $3.08M | Sell |
110,025
-37,361
| -25% | -$1.03M | 0.1% | 165 |
|
|
2024
Q1 | $4.09M | Buy |
147,386
+11,958
| +9% | +$332K | 0.13% | 156 |
|
|
2023
Q4 | $3.9M | Sell |
135,428
-51,315
| -27% | -$1.55M | 0.13% | 157 |
|
|
2023
Q3 | $6.19M | Sell |
186,743
-15,067
| -7% | -$533K | 0.24% | 108 |
|
|
2023
Q2 | $7.4M | Buy |
201,810
+11,627
| +6% | +$453K | 0.27% | 102 |
|
|
2023
Q1 | $7.76M | Sell |
190,183
-45,761
| -19% | -$1.98M | 0.31% | 92 |
|
|
2022
Q4 | $12.1M | Buy |
235,944
+8,596
| +4% | +$412K | 0.52% | 58 |
|
|
2022
Q3 | $9.95M | Buy |
227,348
+1,031
| +0.5% | +$50.1K | 0.47% | 64 |
|
|
2022
Q2 | $11.9M | Buy |
226,317
+10,286
| +5% | +$524K | 0.54% | 55 |
|
|
2022
Q1 | $11.2M | Buy |
216,031
+17,886
| +9% | +$928K | 0.41% | 77 |
|
|
2021
Q4 | $11.7M | Buy |
198,145
+4,364
| +2% | +$216K | 0.39% | 80 |
|
|
2021
Q3 | $8.34M | Buy |
193,781
+6,479
| +3% | +$287K | 0.31% | 98 |
|
|
2021
Q2 | $7.33M | Buy |
187,302
+20,698
| +12% | +$805K | 0.28% | 106 |
|
|
2021
Q1 | $6.04M | Sell |
166,604
-10,256
| -6% | -$364K | 0.25% | 109 |
|
|
2020
Q4 | $6.51M | Sell |
176,860
-2,191
| -1% | -$80.4K | 0.29% | 100 |
|
|
2020
Q3 | $6.23M | Sell |
179,051
-6,842
| -4% | -$240K | 0.32% | 97 |
|
|
2020
Q2 | $5.77M | Sell |
185,893
-2,839
| -2% | -$96.5K | 0.33% | 89 |
|
|
2020
Q1 | $5.83M | Sell |
188,732
-22,579
| -11% | -$769K | 0.41% | 74 |
|
|
2019
Q4 | $7.86M | Sell |
211,311
-58,116
| -22% | -$2.07M | 0.45% | 71 |
|
|
2019
Q3 | $9.19M | Sell |
269,427
-11,174
| -4% | -$406K | 0.59% | 49 |
|
|
2019
Q2 | $11.5M | Buy |
280,601
+3,460
| +1% | +$137K | 0.75% | 38 |
|
|
2019
Q1 | $11.2M | Buy |
277,141
+143,708
| +108% | +$5.76M | 0.77% | 39 |
|
|
2018
Q4 | $5.53M | Sell |
133,433
-35,355
| -21% | -$1.47M | 0.51% | 59 |
|
|
2018
Q3 | $6.97M | Buy |
168,788
+40,193
| +31% | +$1.55M | 0.57% | 48 |
|
|
2018
Q2 | $4.97M | Buy |
128,595
+8,198
| +7% | +$280K | 0.38% | 83 |
|
|
2018
Q1 | $4.05M | Buy |
120,397
+6,495
| +6% | +$223K | 0.34% | 88 |
|
|
2017
Q4 | $3.78M | Buy |
113,902
+15,189
| +15% | +$518K | 0.34% | 89 |
|
|
2017
Q3 | $3.41M | Buy |
98,713
+2,523
| +3% | +$81.1K | 0.4% | 73 |
|
|
2017
Q2 | $3.01M | Sell |
96,190
-2,069
| -2% | -$65.2K | 0.37% | 78 |
|
|
2017
Q1 | $3.08M | Buy |
98,259
+20,552
| +26% | +$648K | 0.38% | 70 |
|
|
2016
Q4 | $2.48M | Buy |
77,707
+5,987
| +8% | +$183K | 0.33% | 86 |
|
|
2016
Q3 | $2.21M | Sell |
71,720
-122
| -0.2% | -$4.08K | 0.32% | 91 |
|
|
2016
Q2 | $2.51M | Buy |
71,842
+103
| +0.1% | +$3.29K | 0.35% | 87 |
|
|
2016
Q1 | $2.02M | Buy |
71,739
+1,890
| +3% | +$54K | 0.31% | 96 |
|
|
2015
Q4 | $2.02M | Buy |
69,849
+902
| +1% | +$28.4K | 0.35% | 83 |
|
|
2015
Q3 | $2.29M | Buy |
68,947
+8,127
| +13% | +$261K | 0.39% | 75 |
|
|
2015
Q2 | $1.94M | Buy |
60,820
+6,320
| +12% | +$206K | 0.34% | 88 |
|
|
2015
Q1 | $1.81M | Buy |
54,500
+6,716
| +14% | +$214K | 0.31% | 91 |
|
|
2014
Q4 | $1.47M | Sell |
47,784
-1,422
| -3% | -$40.8K | 0.28% | 95 |
|
|
2014
Q3 | $1.38M | Buy |
49,206
+5,498
| +13% | +$154K | 0.27% | 103 |
|
|
2014
Q2 | $1.23M | Buy |
43,708
+4,637
| +12% | +$132K | 0.28% | 97 |
|
|
2014
Q1 | $1.19M | Sell |
39,071
-656
| -2% | -$19.6K | 0.31% | 89 |
|
|
2013
Q4 | $1.16M | Buy |
39,727
+933
| +2% | +$27.2K | 0.31% | 89 |
|
|
2013
Q3 | $1.06M | Sell |
38,794
-3,054
| -7% | -$83.1K | 0.33% | 87 |
|
|
2013
Q2 | $1.11M | Buy |
+41,848
| New | +$1.16M | 0.37% | 82 |
|
Other funds holding PFE
AIM
SLAM
CWP
Carnegie Investment Counsel's PFE Position: Q2 2026 in Review
Carnegie Investment Counsel reduced its Pfizer (PFE) stake by 19% in Q2 2026, selling an estimated $817K and leaving 129,803 shares worth $3.13M. The position accounts for 0.06% of the portfolio, ranked #202.
Carnegie Investment Counsel first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.1M in Q4 2022. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Carnegie Investment Counsel held 129,803 shares of Pfizer worth $3.13M as of Q2 2026.
- Carnegie Investment Counsel sold 31,214 Pfizer shares in Q2 2026, an estimated $817K.
- Pfizer made up 0.06% of Carnegie Investment Counsel's portfolio in Q2 2026, its #202 holding.
- Carnegie Investment Counsel first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
- Carnegie Investment Counsel's Pfizer position peaked at $12.1M in Q4 2022.
- 1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Carnegie Investment Counsel's 13F filing for Q2 2026, filed 30 Jul 2026.